支气管袖状切除后镜下残留病变对非小细胞肺癌的临床结局
结果显示R1与R0组在5年总生存率(61.8% vs 61.5%;P=.550)和无复发生存率(53.7% vs 59.0%;P=.390)上无显著差异,且MRD并非独立预后不良因素;但MRD病理浸润深度增加与复发率升高呈显著趋势(P for trend=.015)。
要点
- 支气管袖状切除后切缘镜下残留(MRD)发生率为7.5%,与R0组相比生存无显著差异。
- MRD并非总生存和无复发生存的独立危险因素,吻合口复发率两组相似。
- MRD病理浸润深度越深(向黏膜外浸润性癌进展),复发率呈显著上升趋势。
核心结论
- 在该中心经验中,支气管袖状切除后镜下残留病变并未损害肿瘤学结局。
- MRD的病理浸润范围可能有助于预测复发和制定治疗方案。
研究设计与样本
- 回顾性队列研究,纳入1995年至2015年间连续536例接受支气管袖状切除术的非小细胞肺癌患者。
- 根据支气管切缘状态分组:R0为完全切除,R1为镜下残留肿瘤。
- 中位随访52.4个月(范围0.1-261.0个月)。
主要发现
- R1与R0组5年总生存率分别为61.8%和61.5%(P=.550),无显著差异。
- R1与R0组5年无复发生存率分别为53.7%和59.0%(P=.390),无显著差异。
- 多因素Cox回归显示切缘状态(R1组)与总生存和无复发生存降低无显著关联。
- R1组局部区域复发3例(7.5%),其中吻合口复发1例(2.5%);两组吻合口复发(2.5% vs 2.6%;P=1.000)、局部区域复发(7.5% vs 12.7%;P=.476)和远处复发(25.0% vs 23.2%;P=.947)率均无显著差异。
临床怎么用
- 支气管袖状切除后出现镜下残留病变(R1)时,不必过度解读为预后不良,可结合多学科评估制定后续方案。
- 对于MRD病理浸润较深(向黏膜外浸润性癌进展)的患者,应加强复发监测和个体化治疗规划。
局限性
- 本研究为单中心回顾性分析,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the significance of microscopic residual disease (MRD) at the bronchial resection margin after bronchial sleeve resection in non-small cell lung cancer. METHODS: We retrospectively reviewed 536 consecutive patients who underwent bronchial sleeve resection between 1995 and 2015. Clinical outcomes, including recurrence and long-term survival, were analyzed according to the bronchial resection margin status (R0 = complete resection and R1 = microscopic residual tumor). RESULTS: Forty patients (7.5%) were identified to have MRD. During a 52.4-month follow-up (range, 0.1-261.0 months), there was no significant difference in 5-year overall survival (61.8% vs 61.5%; P = .550) and 5-year recurrence-free survival (53.7% vs 59.0%; P = .390) between groups R1 and R0. Multivariable cox regression analysis demonstrated that the margin status (group R1) was not associated with significantly decreased overall survival and recurrence-free survival. In group R1, 3 patients (7.5%) showed locoregional recurrence, including 1 patient (2.5%) with anastomotic recurrence. There were no significant differences between both groups in anastomotic recurrence (2.5% vs 2.6%; P = 1.000), locoregional recurrence (7.5% vs 12.7%; P = .476), and distant recurrence (25.0% vs 23.2%; P = .947) rates. Subgroup analysis of group R1 revealed a significant trend toward an increasing recurrence rate as the pathological extent of MRD advanced toward invasive extramucosal carcinoma (P for trend = .015). CONCLUSIONS: In our experience of bronchial sleeve resection, the oncologic outcome of MRD was not jeopardized. Furthermore, the pathological extent of MRD might be helpful for recurrence prediction and treatment planning.
引用
- Hong TH, Kim J, Shin S, et al. Clinical outcomes of microscopic residual disease after bronchial sleeve resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020. PMID: 32249083. doi:10.1016/j.jtcvs.2020.02.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。